▼ 1.75%
prev close
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
+1
1 buys · 0 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-11-21 | GHGuardant Health, Inc. | Buy | $1,001 - $15,000 | 184d ago | — |
2025-11-21
Sheldon Whitehouse
GH
Amount
$1,001 - $15,000
Filed
184d ago
Recent News
Powered by Polygon.io
Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
Trade Timeline
Congressional activity, newest first
Sheldon Whitehouse
2025-11-21 · Purchase
$1,001 - $15,000